The serology institute is seeking an emergency license
An Indian foundation prepares to produce an anti-corona virus vaccine
Checking the temperature of a passenger at a train station in India.
Reuters
A giant Indian institution has announced that it will apply, within two weeks, to obtain an emergency license to produce a vaccine against the emerging corona virus (Covid-19).
The CEO of the "Serum Institute of India" (Serum Institute of India), the largest vaccine producer in the world, which is based in the Indian city of Pune, said that the institute will be able, from the beginning of 2021, to produce at least 100 million A monthly dose of the "Coffeeshild" vaccine, which was developed by the company "AstraZenka" in cooperation with the University of Oxford.
Bunawala's statement came after a visit to the institute by the Indian Prime Minister, Narendra Modi, whose government wants 300 to 400 million doses by July of next year.
The pharmaceutical company had initially revealed that its experiments indicated a 70% success rate for the vaccine, and then announced that the percentage jumped to 90% when half an initial dose and then a full dose were given.
"AstraZenka" and the University of Oxford praised their vaccine, because it will be the cheapest among other competing vaccines, and it is easier to store for distribution, because it is easy to handle at higher temperatures.
In addition, the Indian Ministry of Health announced yesterday that 41,810 new cases of Coronavirus had been recorded during the past 24 hours, thus bringing the total number of HIV cases in India to nine million 392,919 cases.
The "NDTV" network quoted the ministry as saying that 496 deaths from the virus were recorded, bringing the total deaths to 136,696 cases.
100
One million doses of the "Coffeeshild" vaccine, the institute will produce each month.
Follow our latest local and sports news, and the latest political and economic developments via Google news